Welcome to our dedicated page for Astrotech news (Ticker: ASTC), a resource for investors and traders seeking the latest updates and insights on Astrotech stock.
Astrotech Corporation (Nasdaq: ASTC) is a mass spectrometry company headquartered in Austin, Texas that develops and commercializes technology-driven businesses through its wholly owned subsidiaries. The Astrotech news stream highlights how its core mass spectrometry and gas chromatography technology is being applied in explosives and narcotics trace detection, aviation and cargo security screening, environmental testing, industrial controls, agriculture process analysis, and breath-based VOC analysis related to infections and critical health conditions.
Visitors to this page can review company press releases and other coverage related to Astrotech’s operating milestones. Recent news has described deployments of 1st Detect’s TRACER 1000 explosive and narcotics trace detection systems at airports and cargo facilities, approvals from security authorities for aviation and air cargo screening, and expansion of 1st Detect’s footprint into new regions such as Southeast Asia. Other updates cover the launch and deployment of EN-SCAN environmental testing instruments that integrate gas chromatography and mass spectrometry for real-time air, water, and soil analysis in the field.
Astrotech’s news also addresses corporate and strategic developments, including financial results, participation in investor conferences, executive appointments, and the Board of Directors’ review of strategic alternatives intended to explore options such as equity capital raises, reverse mergers, combination transactions, or potential sales of parts of the business. Investors and analysts following ASTC can use this page to track how the company’s subsidiaries are progressing in markets like security screening, environmental monitoring, industrial manufacturing, and agriculture, as well as to monitor announcements tied to its strategic review and governance activities.
For anyone researching ASTC stock, this news feed offers a centralized view of Astrotech’s operational updates, technology deployments, and capital markets communications over time.
Astrotech Corporation (NASDAQ: ASTC) reported Q1 FY2021 results, highlighting strategic capital raises totaling $24.2 million to enhance growth opportunities. The company continues to market its TRACER 1000™ explosives trace detector, securing over $1 million in purchase orders. Significant advancements include non-detection testing completion with the TSA, positioning TRACER 1000 for approval. Furthermore, partnerships are established with Cleveland Clinic for the BreathTest-1000™, aimed at rapid infection screening. SG&A and R&D expenses are down, with a reduced monthly cash outlay of $493 thousand.
Astrotech Corporation (NASDAQ: ASTC) has successfully completed a registered direct offering of 2,887,906 shares of its common stock at $2.15 per share, totaling approximately $6.2 million in gross proceeds. The funds will support ongoing operating expenses and working capital. The offering was managed by H.C. Wainwright & Co., utilizing a previously filed shelf registration statement. This capital raise aims to bolster the company's financial standing as it continues to develop innovative technologies in various sectors.
Astrotech Corporation (NASDAQ: ASTC) announced a registered direct offering of 2,887,906 shares at $2.15 each, totaling gross proceeds of $6.2 million, expected to close around October 30, 2020. H.C. Wainwright & Co. is the exclusive placement agent for the offering. The funds will be allocated to ongoing operating expenses and working capital. This offering is conducted under a previously filed shelf registration statement with the SEC.
Astrotech Corporation (NASDAQ: ASTC) announced that its subsidiary, 1st Detect, has secured over $1 million in purchase orders and similar commitments for its TRACER 1000™ explosives trace detector. This technology is currently operational at multiple DHL locations across eight countries in Europe and Asia. The TRACER 1000 is distinguished as the only certified ETD utilizing mass spectrometry, having passed rigorous testing from regulatory bodies like the ECAC and TSA. Executives highlight the growth potential in the recovering transportation sector and areas where high-performance detection is critical.
Astrotech Corporation (NASDAQ: ASTC) has successfully completed a public offering of 7,826,086 shares of common stock at $2.30 per share, generating approximately $18 million in gross proceeds.
The funds will be utilized for ongoing operating expenses and working capital. H.C. Wainwright & Co. served as the exclusive placement agent for the offering. The shares were offered under two SEC registration statements, providing a compliant pathway for this capital raise.
Astrotech Corporation (Nasdaq: ASTC) has announced the pricing of a public offering of 7,826,086 shares of common stock at $2.30 per share, expecting gross proceeds of approximately $18 million. The offering is anticipated to close around October 23, 2020, subject to customary conditions. H.C. Wainwright & Co. is the exclusive placement agent. Proceeds will be used for ongoing operating expenses and working capital. The securities are offered under effective registration statements filed with the SEC.
Astrotech Corporation's subsidiary, BreathTech Corporation, has signed a joint development agreement with Cleveland Clinic to enhance the BreathTest-1000™ mass spectrometer for rapid COVID-19 screening. This partnership aims to create a non-invasive device that identifies COVID-19 strains from breath samples, potentially providing a low-cost, large-scale screening solution. The clinical trial with the technology is expected to commence soon, leveraging the expertise of Dr. Raed Dweik and his research team in detecting diseases through breath analysis.